Business
Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET
WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET. The event will feature a review of the epinephrine drug delivery program, inclusive of the data from the two Phase 1 PK trials and clinical development strategy, and a Q&A discussion. Presentations will be delivered by members of Aquestive’s senior management team and by two prominent Key Opinion Leaders in the field of allergy disorders: David Fleischer, M.D., Section Head, Pediatric Allergy and Immunology at Children’s Hospital Colorado, Professor of Pediatrics at University of Colorado School of MedicineJohn Oppenheimer, M.D., Clinical Professor of Medicine at UMDNJ Rutgers, Pulmonary and Allergy Associates NJ A webcast of the virtual R&D event and accompanying slides will be available under “Events and Presentations” in the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. In addition, the R&D event can be accessed by dialing (833) 640-1722 from the U.S. and (602) 585-9829 internationally, followed by the conference ID: 3598556. The event webcast will be archived for 30 days. About Aquestive Therapeutics Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan® (clobazam) oral film, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization. Forward-Looking Statement This press release includes forward-looking statements within the...